Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of novel protein-based therapeutics as anti-cancer agents. The Company’s products are based on the EVade™ Ribonuclease Technology which allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases.
The EVade™ Ribonuclease technology is covered by patents acquired
by the Company through an exclusive license with the University
of Wisconsin. The Company is in the late pre-clinical stages of
development of QBI-139 and is expecting to file an Investigational
New Drug Application in the first half of 2008. Phase I
human clinical trials are expected to begin soon after filing
the IND. Second generation products are under development
and pre-clinical work is ongoing. |
